Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04884282
Title Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED)
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Fondazione Ricerca Traslazionale
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + OSE 2101

Docetaxel

Nivolumab + OSE 2101

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST